The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The following are the median (interquartile range) total and free concentrations (mg/L): midpoint, total 13.6 (11.2-26.0) and free 1.5 (0.7-2.5); trough, total 11.9 (10.2-22.7) and free 1.8 (0.6-2.6). The percentage free teicoplanin for the mid-dose and trough time points was 6.9% (4.5-15.6%) and 8.2% (5.5-16.4%), respectively. The correlation between total and free antibiotic concentrations was moderate for both the midpoint (ρ = 0.79, P = 0.0021) and trough (ρ = 0.63, P = 0.027). Only 42% and 58% of patients were in the lower and higher therapeutic ranges, respectively. In conclusion, use of standard dosing for teicoplanin leads to inappropriate concentrations in a high proportion of critically ill patients. Variability in teicoplanin protein binding is very high, placing significant doubt on the validity of total concentrations for therapeutic drug monitoring in critically ill patients. © 2014 Elsevier B.V. and the International Society of Chemotherapy.

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

Ranieri V. M.;DeRosa F. G.;
2014

Abstract

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The following are the median (interquartile range) total and free concentrations (mg/L): midpoint, total 13.6 (11.2-26.0) and free 1.5 (0.7-2.5); trough, total 11.9 (10.2-22.7) and free 1.8 (0.6-2.6). The percentage free teicoplanin for the mid-dose and trough time points was 6.9% (4.5-15.6%) and 8.2% (5.5-16.4%), respectively. The correlation between total and free antibiotic concentrations was moderate for both the midpoint (ρ = 0.79, P = 0.0021) and trough (ρ = 0.63, P = 0.027). Only 42% and 58% of patients were in the lower and higher therapeutic ranges, respectively. In conclusion, use of standard dosing for teicoplanin leads to inappropriate concentrations in a high proportion of critically ill patients. Variability in teicoplanin protein binding is very high, placing significant doubt on the validity of total concentrations for therapeutic drug monitoring in critically ill patients. © 2014 Elsevier B.V. and the International Society of Chemotherapy.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
43
5
423
430
Antibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring
Roberts J.A.; Stove V.; De Waele J.J.; Sipinkoski B.; McWhinney B.; Ungerer J.P.J.; Akova M.; Bassetti M.; Dimopoulos G.; Kaukonen K.-M.; Koulenti D.; Martin C.; Montravers P.; Rello J.; Rhodes A.; Starr T.; Wallis S.C.; Lipman J.; Paul S.; Ribas A.M.; DeCrop L.; Spapen H.; Wauters J.; Dugernier T.; Jorens P.; Dapper I.; De Backer D.; Taccone F.S.; Ruano L.; Afonso E.; Alvarez-Lerma F.; Gracia-Arnillas M.P.; Fernandez F.; Feijoo N.; Bardolet N.; Rovira A.; Garro P.; Colon D.; Castillo C.; Fernado J.; Lopez M.J.; Fernandez J.L.; Arribas A.M.; Teja J.L.; Ots E.; Montejo J.C.; Catalan M.; Prieto I.; Gonzalo G.; Galvan B.; Blasco M.A.; Meyer E.; Nogal F.D.; Vidaur L.; Sebastian R.; Garde P.M.; Velasco Mdel M.; Crespo R.Z.; Esperatti M.; Torres A.; Baldesi O.; Dupont H.; Mahjoub Y.; Lasocki S.; Constantin J.M.; Payen J.F.; Albanese J.; Malledant Y.; Pottecher J.; Lefrant J.Y.; Jaber S.; Joannes-Boyau O.; Orban C.; Ostermann M.; McKenzie C.; Berry W.; Smith J.; Lei K.; Rubulotta F.; Gordon A.; Brett S.; Stotz M.; Templeton M.; Ebm C.; Moran C.; Pettila V.; Xristodoulou A.; Theodorou V.; Kouliatsis G.; Sertaridou E.; Anthopoulos G.; Choutas G.; Rantis T.; Karatzas S.; Balla M.; Papanikolaou M.; Myrianthefs P.; Gavala A.; Fildisis G.; Koutsoukou A.; Kyriakopoulou M.; Petrochilou K.; Kompoti M.; Michalia M.; Clouva-Molyvdas F.M.; Gkiokas G.; Nikolakopoulos F.; Psychogiou V.; Malliotakis P.; Akoumianaki E.; Lilitsis E.; Koulouras V.; Nakos G.; Kalogirou M.; Komnos A.; Zafeiridis T.; Chaintoutis C.; Arvaniti K.; Matamis D.; Kydona C.; Gritsi-Gerogianni N.; Giasnetsova T.; Giannakou M.; Soultati I.; Chytas I.; Antoniadou E.; Antipa E.; Lathyris D.; Koukoubani T.; Paraforou T.; Spiropoulou K.; Bekos V.; Spring A.; Kalatzi T.; Nikolaou H.; Laskou M.; Strouvalis I.; Aloizos S.; Kapogiannis S.; Soldatou O.; Adembri C.; Villa G.; Giarratano A.; Raineri S.M.; Cortegiani A.; Montalto F.; Strano M.T.; Ranieri V.M.; Sandroni C.; De Pascale G.; Molin A.; Pelosi P.; Montagnani L.; Urbino R.; Mastromauro I.; DeRosa F.G.; Cardoso T.; Afonso S.; Goncalves-Pereira J.; Baptista J.P.; Ozveren A.
File in questo prodotto:
File Dimensione Formato  
variability teicoplanin Int J Antimicrob ag 2014.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 670.61 kB
Formato Adobe PDF
670.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1797787
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 36
social impact